Table 2.

Aminoglycoside resistance phenotypes

StrainPatient and/or relevant genotypebAGRP zone diameter (mm)aDisc AGRP Phenotype
ApraForta2156221561GentTobraAmkIsepNet22591KanNeo
PAO1Wild type20201716162121201818814Sensitive
2547Isogenic PAO1 mutant10677610678966Permeability
2548Isogenic 2547 mutant666666666666Permeability
116840-03, 22-720191616162017181617612Sensitive
125040-03, 22-71986610191213111666Permeability
124940-03, 22-7666666666666Permeability
115159-01, 11-12722202021272322222366Sensitive
103059-01, 10-18669618610111266Permeability
120059-01, 10-1666666666666Permeability
91348-06, 7-1292928282529303030251018Sensitive
108548-07, 7-127282526222624242422916Sensitive
136547-17, 4-130212222233128272726616Sensitive
145701-09, ND262021212127242522221116Sensitive
110450-03, 24-4666666666666Permeability
145267-03, ND666666666666Permeability
152053-11, ND666666666666Permeability
  • a Disk diameter is 6 mm. A value of 6 mm indicates no zone of inhibition. Apra, apramycin; Forta, fortamicin; Gent, gentamicin; Tobra, tobramycin; Amk, amikacin; Isep, isepamicin; Net, netilmicin; Kan, kanamycin; Neo, neomycin.

  • b Genotypes for the clinical isolates were determined by randomly amplified polymorphic DNA fingerprinting as described by Bukanov et al. (7). ND, not determined.